15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Increased Prevalence of Fractures in Congenital Adrenal Hyperplasia: A Swedish Population-based National Cohort Study

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Context

          Low bone mineral density has been reported in individuals with congenital adrenal hyperplasia (CAH), but the prevalence of fractures is unclear.

          Objective

          To study the prevalence of fractures in CAH.

          Design, Setting, and Participants

          Patients with CAH (n = 714, all 21-hydroxylase deficiency) were compared with controls matched for sex and year and place of birth (n = 71 400). Data were derived by linking National Population-Based Registers.

          Main Outcome Measures

          Number and type of fractures.

          Results

          Mean age was 29.8 ± 18.4 years. Individuals with CAH had more fractures compared to controls [23.5% vs 16.1%, odds ratio (OR) 1.61, 95% CI 1.35-1.91], and this was found in both sexes (females: 19.6% vs 13.3%, OR 1.57, 95% CI 1.23-2.02; males: 28.7% vs 19.6%, OR 1.65, 95% CI 1.29-2.12). Fractures were significantly increased in patients born before the introduction of neonatal screening but not in those born afterwards. Any major fracture associated with osteoporosis (spine, forearm, hip, or shoulder) was increased in all individuals with CAH (9.8% vs 7.5%, OR 1.34, 95% CI 1.05-1.72). The highest prevalence of fractures was seen in SV phenotype and I172N genotype while nonclassic phenotype and I2 splice genotype did not show increased prevalence. A transport accident as a car occupant and fall on the same level were more common in patients with CAH, both sexes, than in controls.

          Conclusions

          Patients with CAH had an increased prevalence of both any fracture and fractures associated with osteoporosis (both sexes) but not for patients neonatally screened. We conclude that fracture risk assessment and glucocorticoid optimization should be performed regularly.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline

          To update the congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency clinical practice guideline published by the Endocrine Society in 2010.
            • Record: found
            • Abstract: not found
            • Article: not found

            Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment

              • Record: found
              • Abstract: found
              • Article: not found

              Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management

              Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders affecting cortisol biosynthesis. Reduced activity of an enzyme required for cortisol production leads to chronic overstimulation of the adrenal cortex and accumulation of precursors proximal to the blocked enzymatic step. The most common form of CAH is caused by steroid 21-hydroxylase deficiency due to mutations in CYP21A2. Since the last publication summarizing CAH in Endocrine Reviews in 2000, there have been numerous new developments. These include more detailed understanding of steroidogenic pathways, refinements in neonatal screening, improved diagnostic measurements utilizing chromatography and mass spectrometry coupled with steroid profiling, and improved genotyping methods. Clinical trials of alternative medications and modes of delivery have been recently completed or are under way. Genetic and cell-based treatments are being explored. A large body of data concerning long-term outcomes in patients affected by CAH, including psychosexual well-being, has been enhanced by the establishment of disease registries. This review provides the reader with current insights in CAH with special attention to these new developments.

                Author and article information

                Journal
                J Clin Endocrinol Metab
                J Clin Endocrinol Metab
                jcem
                The Journal of Clinical Endocrinology and Metabolism
                Oxford University Press (US )
                0021-972X
                1945-7197
                February 2022
                03 October 2021
                03 October 2021
                : 107
                : 2
                : e475-e486
                Affiliations
                [1 ] Department of Endocrinology, Karolinska University Hospital , Stockholm, Sweden
                [2 ] Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm, Sweden
                [3 ] Department of Clinical Neuroscience, Karolinska Institutet , Stockholm, Sweden
                [4 ] Child and Adolescent Psychiatry Research Center , Stockholm, Sweden
                [5 ] Department of Women’s and Children’s Health, Karolinska Institutet , Stockholm, Sweden
                [6 ] Department of Gynecology and Reproductive Medicine, Karolinska University Hospital , Stockholm, Sweden
                [7 ] Center for Molecular Medicine, Karolinska Institutet , Stockholm, Sweden
                [8 ] Pediatric Surgery, Astrid Lindgren Children’s Hospital, Karolinska University Hospital , Stockholm, Sweden
                [9 ] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm, Sweden
                [10 ] Lung and Allergy Unit, Astrid Lindgren Children’s Hospital, Karolinska University Hospital
                [11 ] Department of Pediatric Endocrinology, Astrid Lindgren Children’s Hospital, Karolinska University Hospital , Stockholm, Sweden
                Author notes
                Correspondence: Henrik Falhammar, MD, PhD, FRACP, Department of Molecular Medicine and Surgery, QB8:05, Karolinska Institutet, SE-171 76 Stockholm, Sweden. E-mail: henrik.falhammar@ 123456ki.se .
                Author information
                https://orcid.org/0000-0002-5622-6987
                https://orcid.org/0000-0002-8254-6183
                https://orcid.org/0000-0001-6481-6277
                https://orcid.org/0000-0001-6638-4631
                https://orcid.org/0000-0002-1045-1898
                https://orcid.org/0000-0003-0405-3401
                Article
                dgab712
                10.1210/clinem/dgab712
                8764334
                34601607
                bed2aa03-e7ed-43a0-93db-4b39e0fa5c9d
                © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 24 June 2021
                : 24 September 2021
                : 15 October 2021
                Page count
                Pages: 12
                Funding
                Funded by: Magnus Bergvall Foundation, DOI 10.13039/501100006285;
                Funded by: Karolinska Institutet, DOI 10.13039/501100004047;
                Funded by: Stockholm County Council, DOI 10.13039/501100004348;
                Funded by: Swedish Research Council, DOI 10.13039/501100004359;
                Award ID: 2017-02051
                Funded by: Swedish Initiative for Research on Microdata in the Social and Medical Sciences;
                Award ID: 340-2013-5867
                Categories
                Online Only Articles
                Clinical Research Articles
                AcademicSubjects/MED00250

                Endocrinology & Diabetes
                21-hydroxylase deficiency,osteoporosis,trauma,bone mineral density,fall
                Endocrinology & Diabetes
                21-hydroxylase deficiency, osteoporosis, trauma, bone mineral density, fall

                Comments

                Comment on this article

                Related Documents Log